{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:08:05Z","timestamp":1771708085671,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations. However, the material of the dialysis membrane remains unknown. In addition, there have been no reports on the effects of continuous hemodiafiltration. In this study, we investigated the effects of continuous hemodiafiltration on tedizolid using two types of dialysis membranes made of different materials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The adsorption of tedizolid, linezolid, and vancomycin to two different dialysis membranes was investigated, and the clearance of each drug was calculated by experiments using an in vitro continuous hemodiafiltration model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The adsorption of tedizolid, linezolid, and vancomycin on the dialysis membranes was examined, and no adsorption was observed. Experimental results from the continuous hemodiafiltration model showed that linezolid and vancomycin concentrations decreased over time: after two hours, the respective decreases were 26.48\u2009\u00b1\u20097.14% and 28.51\u2009\u00b1\u20092.32% for polysulfone membranes, respectively. The decrease was 23.57\u2009\u00b1\u20094.95% and 28.73\u2009\u00b1\u20095.13% for the polymethylmethacrylate membranes, respectively. These results suggested that linezolid and vancomycin were eliminated by continuous hemodiafiltration. In contrast, tedizolid phosphate and tedizolid concentrations decreased slightly in the polysulfone and polymethylmethacrylate membranes. The decrease in concentrations were 2.10\u2009\u00b1\u20090.77% and 2.97\u2009\u00b1\u20090.60% for the polysulfone membranes, respectively. For the polymethylmethacrylate membranes, the decrease in concentration were 2.01\u2009\u00b1\u20090.88% and 1.73\u2009\u00b1\u20090.27%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results suggested that tedizolid should not be considered for dose control during continuous hemodiafiltration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-023-00307-9","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:02:02Z","timestamp":1699920122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model"],"prefix":"10.1186","volume":"9","author":[{"given":"Satoshi","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"307_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46:997\u20131038. https:\/\/doi.org\/10.2165\/00003088-200746120-00003.","journal-title":"Clin Pharmacokinet"},{"key":"307_CR2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","volume":"37","author":"G Choi","year":"2009","unstructured":"Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn RC, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268\u201382. https:\/\/doi.org\/10.1097\/CCM.0b013e3181aab3d0.","journal-title":"Crit Care Med"},{"key":"307_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11095-020-02820-0","volume":"37","author":"K Oda","year":"2020","unstructured":"Oda K, Jono H, Kamohara H, Nishi K, Tanoue N, Saito H. Development of vancomycin dose individualization strategy by bayesian prediction in patients receiving continuous renal replacement therapy. Pharm Res. 2020;37:108. https:\/\/doi.org\/10.1007\/s11095-020-02820-0.","journal-title":"Pharm Res"},{"key":"307_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000014313","volume":"16","author":"UF Kroh","year":"1998","unstructured":"Kroh UF, Dinges GK, Lukasewitz P, Steinh\u00e4usser WU, Holl TJ, Lennartz H. Elimination of drugs by the new polyamide hemofilter FH77H during various in vitro conditions. Blood Purif. 1998;16:49\u201356. https:\/\/doi.org\/10.1159\/000014313.","journal-title":"Blood Purif"},{"key":"307_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1128\/AAC.00858-07","volume":"52","author":"Q Tian","year":"2008","unstructured":"Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008;52:1009\u201313. https:\/\/doi.org\/10.1128\/AAC.00858-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"307_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijantimicag.2006.03.025","volume":"28","author":"Q Tian","year":"2006","unstructured":"Tian Q, Gomersall CD, Wong A, Leung P, Choi G, Joynt GM, et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int J Antimicrob Agents. 2006;28:147\u201350. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.03.025.","journal-title":"Int J Antimicrob Agents"},{"key":"307_CR7","first-page":"4","volume":"6","author":"DA Santini","year":"2015","unstructured":"Santini DA, Sutherland CA, Nicolau DP. Development of a high-performance liquid chromatography method for the determination of tedizolid in human plasma, human serum, saline and mouse plasma. J Chromatogr Sep Tech. 2015;6:4.","journal-title":"J Chromatogr Sep Tech"},{"key":"307_CR8","doi-asserted-by":"publisher","unstructured":"Dorn C, Schie\u00dfer S, Wulkersdorfer B, Hitzenbichler F, Kees MG, Zeitlinger M. Determination of free clindamycin, flucloxacillin or tedizolid in plasma: Pay attention to physiological conditions when using ultrafiltration. Biomed Chromatogr. 2020;34:e4820. https:\/\/doi.org\/10.1002\/bmc.4820.","DOI":"10.1002\/bmc.4820"},{"key":"307_CR9","first-page":"030","volume":"7","author":"A Anerao","year":"2017","unstructured":"Anerao A, Dighe V, John S, Pradhan N. Enantioseparation of tedizolid phosphate by RP-HPLC, using-cyclodextrin as a chiral mobile phase additive. J Appl Pharm Sci. 2017;7:030\u20136.","journal-title":"J Appl Pharm Sci"},{"key":"307_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/0310057X1204000309","volume":"40","author":"Y Shiraishi","year":"2012","unstructured":"Shiraishi Y, Okajima M, Sai Y, Miyamoto K, Inaba H. Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: Screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin. Anaesth Intensive Care. 2012;40:442\u20139. https:\/\/doi.org\/10.1177\/0310057X1204000309.","journal-title":"Anaesth Intensive Care"},{"key":"307_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2147\/DDDT.S136335","volume":"11","author":"R Taylor","year":"2017","unstructured":"Taylor R, Sunderland B, Luna G, Czarniak P. Evaluation of the stability of linezolid in aqueous solution and commonly used intravenous fluids. Drug Des Devel Ther. 2017;11:2087\u201397. https:\/\/doi.org\/10.2147\/DDDT.S136335.","journal-title":"Drug Des Devel Ther"},{"key":"307_CR12","first-page":"104","volume":"25","author":"T Kitahashi","year":"1996","unstructured":"Kitahashi T, Ohba Y. Determination of vancomycin in blood by direct serum infusion high-performance liquid chromatography. Clin Chem. 1996;25:104\u20138.","journal-title":"Clin Chem"},{"key":"307_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40064-016-1778-4","volume":"5","author":"M Usman","year":"2016","unstructured":"Usman M, Hempel G. Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA). Springerplus. 2016;5:124.","journal-title":"Springerplus"},{"key":"307_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/chromsci\/bmx089","volume":"56","author":"TM Lima","year":"2018","unstructured":"Lima TM, Seba KS, Gon\u00e7alves JCS, Cardoso FLL, Estrela FLL, Estrela RCE. A rapid and simple HPLC method for therapeutic monitoring of vancomycin. J Chromatogr Sci. 2018;56:115\u201321. https:\/\/doi.org\/10.1093\/chromsci\/bmx089.","journal-title":"J Chromatogr Sci"},{"key":"307_CR15","unstructured":"Shimizu T, Karube I, Yoshikawa M, Tamiya E. Medical membrane materials biofunctional similarity membranes. Tokyo: Kyoritsu Publishing Co; 1994. p. 260\u2013342."},{"key":"307_CR16","unstructured":"Kawasaki T. Dialyzer. Blood purification equipment. 1994 issue of clinical dialysis, Japan medical center. Tokyo: 1994:1001\u201329."},{"key":"307_CR17","unstructured":"Kawata I, Suhara G, Sueoka A. Characteristics of adsorption of \u03b22-microglobulin according to \u00a0various materials of membranes. Kidney Dial. 1988;59\u201363."},{"key":"307_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/FTD.0000000000000721","volume":"42","author":"S Yamazaki","year":"2020","unstructured":"Yamazaki S, Tatebe M, Fujiyoshi M, Hattori N, Suzuki T, Takatsuka H, et al. Population pharmacokinetics of vancomycin under continuous renal replacement therapy using a polymethylmethacrylate hemofilter. Ther Drug Monit. 2020;42:452\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000000721.","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-023-00307-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-023-00307-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:14:19Z","timestamp":1700324059000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-023-00307-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1186\/s40780-023-00307-9","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}